Lately new improvements in cytogenetic, immunophenotyping, and molecular biology have significantly propelled our comprehension of leukemia. Tragically, customary morphologic assessment of intense myeloblastic leukemia utilizing the French-American-British characterization corresponds ineffectively with a large portion of this new data and does not anticipate reaction to treatment. In this audit we focus on uses of molecular biologic procedures to the determination of leukemia, and examine utilization of this innovation to identify insignificant lingering illness. We at that point present an amended grouping for intense myeloblastic leukemia as indicated by whether myelodysplasia-like highlights are available or lacking. Cases may then be additionally characterized utilizing French-American-British morphology and different parameters. This grouping seems to relate better with new biologic information and with remedial reaction.